Literature DB >> 9699728

CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas.

R M MacKie1, N Andrew, W G Lanyon, J M Connor.   

Abstract

We report six of 16 U.K. melanoma families and two of 17 patients with multiple primary melanomas and a negative family history who have between them four different functionally damaging mutations of the CDKN2A (p16) gene: an Arg 24 Pro substitution in exon 1 in one family, a stop codon at codon 44 of exon 1 in one family, and a Met 53 Ile substitution in exon 2 in four families. One multiple primary melanoma patient also has the Met 53 Ile mutation and a second has a G-T substitution at the IVS2 + 1 splice donor site. Our data together with other recent publications from France and the U.S.A. indicate that screening melanoma kindreds with only two affected family members for CDKN2A mutations is justified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699728     DOI: 10.1046/j.1523-1747.1998.00267.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.

Authors:  C Yuan; T L Selby; J Li; I J Byeon; M D Tsai
Journal:  Protein Sci       Date:  2000-06       Impact factor: 6.725

2.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

Review 3.  New developments in melanoma genetics.

Authors:  N Hayward
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 4.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

5.  The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.

Authors:  Janice A Royds; Shafagh Al Nadaf; Anna K Wiles; Yu-Jen Chen; Antonio Ahn; Alisha Shaw; Sara Bowie; Frederic Lam; Bruce C Baguley; Antony W Braithwaite; Martin R MacFarlane; Noelyn A Hung; Tania L Slatter
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

6.  A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.

Authors:  A M Goldstein; L Liu; M G Shennan; D Hogg; M A Tucker; J P Struewing
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

7.  Analysis of p16 expression and allelic imbalance / loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas.

Authors:  Sarah E Gray; Elaine Kay; Mary Leader; M Mabruk
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

Review 8.  CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

Authors:  Sock Hoai Chan; Jianbang Chiang; Joanne Ngeow
Journal:  Hered Cancer Clin Pract       Date:  2021-03-25       Impact factor: 2.857

9.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Authors:  Edyta Borkowska; Adam Jędrzejczyk; Andrzej Kruk; Michał Pietrusiński; Magdalena Traczyk; Marek Rożniecki; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2011-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.